大阪急性期・総合医療センターとは、 大阪府大阪市住吉区にある医療機関である。略称は、府立総医療センターである。

During the past decade, Osaka General Medical Center conducted 29 clinical trials. In the 10-year time frame, 29 clinical trials started and 10 clinical trials were completed, i.e. on average, 34.5% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 8 clinical trials were completed. i.e. 53.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Osaka General Medical Center" #1 sponsor was "Bayer" with 12 trials, followed by "Pfizer" with 3 trials sponsored, "Chugai Pharmaceutical" with 2 trials sponsored, "Daiichi Sankyo Co., Ltd." with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Osaka General Medical Center" #1 collaborator was "Japan Lung Cancer Society" with 2 trials as a collaborator, "Accelerated Care Plus" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Osaka General Medical Center" are "Heart Failure" (6 trials), "Anemia" (3 trials), "Gastric Cancer" (3 trials), "Renal Insufficiency, Chronic" (3 trials) and "Acute Myocardial Infarction" (2 trials). Many other conditions were trialed in "Osaka General Medical Center" in a lesser frequency.

Most popular intervention types in "Osaka General Medical Center" are "Drug" (35 trials), "Other" (6 trials), "Device" (4 trials), "Biological" (3 trials) and "Procedure" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Molidustat (BAY85-3934)" (3 trials), "Darbepoetin alfa" (2 trials), "Finerenone (BAY94-8862)" (2 trials) and "Neladenoson bialanate (BAY1067197)" (2 trials). Other intervention names were less common.

The vast majority of trials in "Osaka General Medical Center" are 43 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Osaka General Medical Center". undefined are not yet recruiting, 8 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Osaka General Medical Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Osaka General Medical Center, 0 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 3 trials that are defined as “Not Applicable".